,Contents
Chapter 01: The Nursing Process and Patient-Centered Care ..................................................................... 3
Chapter 02: Drug Development and Ethical Considerations ...................................................................... 9
Chapter 03: Pharmacokinetics and Pharmacodynamics ............................................................................ 16
Chapter 04: Pharmacogenetics .................................................................................................................. 28
Chapter 05: Complementary and Alternative Therapies ........................................................................... 30
Chapter 06: Pediatric Considerations ........................................................................................................ 35
Chapter 07: Geriatric Considerations ........................................................................................................ 41
Chapter 08: Drugs in Substance Use Disorder .......................................................................................... 45
Chapter 09: Safety and Quality ................................................................................................................. 51
Chapter 10: Drug Administration .............................................................................................................. 57
Chapter 11: Drug Calculations .................................................................................................................. 62
Chapter 12: Fluid Volume and Electrolytes .............................................................................................. 66
Chapter 13: Vitamin and Mineral Replacement ........................................................................................ 74
Chapter 14: Nutritional Support ................................................................................................................ 81
Chapter 15: Adrenergic Agonists and Antagonists ................................................................................... 87
Chapter 16: Cholinergic Agonists and Antagonists .................................................................................. 93
Chapter 17: Stimulants .............................................................................................................................. 98
Chapter 18: Depressants .......................................................................................................................... 102
Chapter 19: Antiseizure Drugs ................................................................................................................ 107
Chapter 20: Drugs for Parkinsonism and Alzheimer Disease ................................................................. 113
Chapter 21: Drugs for Neuromuscular Disorders and Muscle Spasms ................................................... 120
Chapter 22: Antipsychotics and Anxiolytics ........................................................................................... 126
Chapter 23: Antidepressants and Mood Stabilizers ................................................................................ 133
Chapter 24: Antiinflammatories .............................................................................................................. 139
Chapter 25: Analgesics ............................................................................................................................ 146
Chapter 26: Penicillins, Other Beta-Lactams, and Cephalosporins ........................................................ 151
Chapter 27: Macrolides, Oxazolidinones, Lincosamides, Glycopeptides, Ketolides, and Lipopeptides 157
Chapter 28: Tetracyclines, Glycylcyclines, Aminoglycosides, and Fluoroquinolones ........................... 161
Chapter 29: Sulfonamides and Nitroimidazoles ...................................................................................... 164
Chapter 30: Antituberculars, Antifungals, and Antivirals ....................................................................... 168
Chapter 31: Antimalarials, Anthelmintics, and Peptides ........................................................................ 175
Chapter 32: HIV- and AIDS-Related Drugs ........................................................................................... 178
Chapter 33: Transplant Drugs ................................................................................................................. 182
Chapter 34: Vaccines............................................................................................................................... 185
Chapter 35: Anticancer Drugs ................................................................................................................. 188
Chapter 36: Targeted Therapies to Treat Cancer .................................................................................... 193
,Chapter 37: Biologic Response Modifiers .............................................................................................. 197
Chapter 38: Upper Respiratory Disorders ............................................................................................... 201
Chapter 39: Lower Respiratory Disorders............................................................................................... 206
Chapter 40: Cardiac Glycosides, Antianginals, and Antidysrhythmics .................................................. 213
Chapter 41: Diuretics............................................................................................................................... 222
Chapter 42: Antihypertensives ................................................................................................................ 227
Chapter 43: Anticoagulants, Antiplatelets, and Thrombolytics .............................................................. 235
Chapter 44: Antihyperlipidemics and Drugs to Improve Peripheral Blood Flow ................................... 243
Chapter 45: Gastrointestinal Tract Disorders .......................................................................................... 250
Chapter 46: Antiulcer Drugs ................................................................................................................... 257
Chapter 47: Eye and Ear Disorders ......................................................................................................... 264
Chapter 48: Dermatologic Disorders ....................................................................................................... 269
Chapter 49: Pituitary, Thyroid, Parathyroid, and Adrenal Disorders ...................................................... 274
Chapter 50: Antidiabetics ........................................................................................................................ 283
Chapter 51: Urinary Disorders ................................................................................................................ 291
Chapter 52: Pregnancy and Preterm Labor ............................................................................................. 297
Chapter 53: Labor, Delivery, and Postpartum ......................................................................................... 304
Chapter 54: Neonatal and Newborn ........................................................................................................ 311
Chapter 55: Women’s Reproductive Health ........................................................................................... 313
Chapter 56: Men’s Health and Reproductive Disorders ......................................................................... 321
Chapter 57: Sexually Transmitted Infections .......................................................................................... 327
Chapter 58: Adult and Pediatric Emergency Drugs ................................................................................ 330
Chapter 01: The Nursing Process and Patient-Centered Care
McCuistion: Pharmacology: A Patient-Centered Nursing Process Approach, 11th Edition
MULTIPLE CHOICE
1. An older patient must learn to administer a medication using a device that requires manual
dexterity. The patient becomes frustrated and expresses lack of self-confidence in performing
this task. Which action will the nurse perform next?
a. Ask the patient to keep trying until the skill is learned.
b. Provide written instructions with illustrations showing each step of the skill.
c. Schedule multiple sessions and practice each step separately.
d. Teach the procedure to family members who can administer the medication for the patient.
ANS: C
Nurses should be sensitive to patient’s level of frustration when teaching skills. In this case,
breaking the steps down into individual parts will help with this patient’s frustration level.
DIF: Cognitive Level: Applying (Application) TOP: Nursing Process: Planning MSC: NCLEX:
Management of Client Care
, 2. The nurse is developing a teaching plan for an elderly patient who will begin taking an
antihypertensive drug that causes dizziness and orthostatic hypotension. Which hypothesis
(problem) documented by the nurse is appropriate for this patient?
a. Deficient knowledge related to drug side effects.
b. Ineffective health maintenance related to age.
c. Readiness for enhanced knowledge related to medication side effects.
d. Risk for injury related to side effects of the medication.
ANS: D
This patient has an increased risk for injury because of drug side effects, so this is an appropriate
hypothesis (problem) to direct the type of care and follow-up the patient will receive.
DIF: Cognitive Level: Applying (Application)
TOP: Nursing Process: Nursing Diagnosis
MSC: NCLEX: Management of Client Care
3. All of the following would be considered subjective data, EXCEPT:
a. Patient-reported health history
b. Patient-reported signs and symptoms of their illness
c. Financial barriers reported by the patient’s caregiver
d. Vital signs obtained from the medical record
ANS: D
Subjective data is based on what patients or family members communicate to the nurse. Patient-
reported health history, signs and symptoms, and caregiver reported financial barriers would be
considered subjective data. Vital signs obtained from the medical record would be considered
objective data.
DIF: Cognitive Level: Understanding (Comprehension) TOP: Nursing Process: Planning MSC: NCLEX:
Management of Client Care
4. The nurse is generating solutions (planning) for a patient who has chronic lung disease and
hypoxia. The patient has been admitted for increased oxygen needs above a baseline of 2 L/min.
The nurse generates an expected outcomes stating, “The patient will have oxygen saturations of
>95% on room air at the time of discharge from the hospital.” What is wrong with this goal?
a. It cannot be evaluated.
b. It is not measurable.
c. It is not patient-centered.
d. It is not realistic.
ANS: D
The expected outcome is not realistic because the patient is not usually on room air and should
not be expected to attain that expected outcome by discharge from this hospitalization.
DIF: Cognitive Level: Applying (Application) TOP: Nursing Process: Planning MSC: NCLEX:
Management of Client Care
5. Which of the following would be correctly categorized as objective data?
a. A list of herbal supplements regularly used provided by the patient.
Chapter 01: The Nursing Process and Patient-Centered Care ..................................................................... 3
Chapter 02: Drug Development and Ethical Considerations ...................................................................... 9
Chapter 03: Pharmacokinetics and Pharmacodynamics ............................................................................ 16
Chapter 04: Pharmacogenetics .................................................................................................................. 28
Chapter 05: Complementary and Alternative Therapies ........................................................................... 30
Chapter 06: Pediatric Considerations ........................................................................................................ 35
Chapter 07: Geriatric Considerations ........................................................................................................ 41
Chapter 08: Drugs in Substance Use Disorder .......................................................................................... 45
Chapter 09: Safety and Quality ................................................................................................................. 51
Chapter 10: Drug Administration .............................................................................................................. 57
Chapter 11: Drug Calculations .................................................................................................................. 62
Chapter 12: Fluid Volume and Electrolytes .............................................................................................. 66
Chapter 13: Vitamin and Mineral Replacement ........................................................................................ 74
Chapter 14: Nutritional Support ................................................................................................................ 81
Chapter 15: Adrenergic Agonists and Antagonists ................................................................................... 87
Chapter 16: Cholinergic Agonists and Antagonists .................................................................................. 93
Chapter 17: Stimulants .............................................................................................................................. 98
Chapter 18: Depressants .......................................................................................................................... 102
Chapter 19: Antiseizure Drugs ................................................................................................................ 107
Chapter 20: Drugs for Parkinsonism and Alzheimer Disease ................................................................. 113
Chapter 21: Drugs for Neuromuscular Disorders and Muscle Spasms ................................................... 120
Chapter 22: Antipsychotics and Anxiolytics ........................................................................................... 126
Chapter 23: Antidepressants and Mood Stabilizers ................................................................................ 133
Chapter 24: Antiinflammatories .............................................................................................................. 139
Chapter 25: Analgesics ............................................................................................................................ 146
Chapter 26: Penicillins, Other Beta-Lactams, and Cephalosporins ........................................................ 151
Chapter 27: Macrolides, Oxazolidinones, Lincosamides, Glycopeptides, Ketolides, and Lipopeptides 157
Chapter 28: Tetracyclines, Glycylcyclines, Aminoglycosides, and Fluoroquinolones ........................... 161
Chapter 29: Sulfonamides and Nitroimidazoles ...................................................................................... 164
Chapter 30: Antituberculars, Antifungals, and Antivirals ....................................................................... 168
Chapter 31: Antimalarials, Anthelmintics, and Peptides ........................................................................ 175
Chapter 32: HIV- and AIDS-Related Drugs ........................................................................................... 178
Chapter 33: Transplant Drugs ................................................................................................................. 182
Chapter 34: Vaccines............................................................................................................................... 185
Chapter 35: Anticancer Drugs ................................................................................................................. 188
Chapter 36: Targeted Therapies to Treat Cancer .................................................................................... 193
,Chapter 37: Biologic Response Modifiers .............................................................................................. 197
Chapter 38: Upper Respiratory Disorders ............................................................................................... 201
Chapter 39: Lower Respiratory Disorders............................................................................................... 206
Chapter 40: Cardiac Glycosides, Antianginals, and Antidysrhythmics .................................................. 213
Chapter 41: Diuretics............................................................................................................................... 222
Chapter 42: Antihypertensives ................................................................................................................ 227
Chapter 43: Anticoagulants, Antiplatelets, and Thrombolytics .............................................................. 235
Chapter 44: Antihyperlipidemics and Drugs to Improve Peripheral Blood Flow ................................... 243
Chapter 45: Gastrointestinal Tract Disorders .......................................................................................... 250
Chapter 46: Antiulcer Drugs ................................................................................................................... 257
Chapter 47: Eye and Ear Disorders ......................................................................................................... 264
Chapter 48: Dermatologic Disorders ....................................................................................................... 269
Chapter 49: Pituitary, Thyroid, Parathyroid, and Adrenal Disorders ...................................................... 274
Chapter 50: Antidiabetics ........................................................................................................................ 283
Chapter 51: Urinary Disorders ................................................................................................................ 291
Chapter 52: Pregnancy and Preterm Labor ............................................................................................. 297
Chapter 53: Labor, Delivery, and Postpartum ......................................................................................... 304
Chapter 54: Neonatal and Newborn ........................................................................................................ 311
Chapter 55: Women’s Reproductive Health ........................................................................................... 313
Chapter 56: Men’s Health and Reproductive Disorders ......................................................................... 321
Chapter 57: Sexually Transmitted Infections .......................................................................................... 327
Chapter 58: Adult and Pediatric Emergency Drugs ................................................................................ 330
Chapter 01: The Nursing Process and Patient-Centered Care
McCuistion: Pharmacology: A Patient-Centered Nursing Process Approach, 11th Edition
MULTIPLE CHOICE
1. An older patient must learn to administer a medication using a device that requires manual
dexterity. The patient becomes frustrated and expresses lack of self-confidence in performing
this task. Which action will the nurse perform next?
a. Ask the patient to keep trying until the skill is learned.
b. Provide written instructions with illustrations showing each step of the skill.
c. Schedule multiple sessions and practice each step separately.
d. Teach the procedure to family members who can administer the medication for the patient.
ANS: C
Nurses should be sensitive to patient’s level of frustration when teaching skills. In this case,
breaking the steps down into individual parts will help with this patient’s frustration level.
DIF: Cognitive Level: Applying (Application) TOP: Nursing Process: Planning MSC: NCLEX:
Management of Client Care
, 2. The nurse is developing a teaching plan for an elderly patient who will begin taking an
antihypertensive drug that causes dizziness and orthostatic hypotension. Which hypothesis
(problem) documented by the nurse is appropriate for this patient?
a. Deficient knowledge related to drug side effects.
b. Ineffective health maintenance related to age.
c. Readiness for enhanced knowledge related to medication side effects.
d. Risk for injury related to side effects of the medication.
ANS: D
This patient has an increased risk for injury because of drug side effects, so this is an appropriate
hypothesis (problem) to direct the type of care and follow-up the patient will receive.
DIF: Cognitive Level: Applying (Application)
TOP: Nursing Process: Nursing Diagnosis
MSC: NCLEX: Management of Client Care
3. All of the following would be considered subjective data, EXCEPT:
a. Patient-reported health history
b. Patient-reported signs and symptoms of their illness
c. Financial barriers reported by the patient’s caregiver
d. Vital signs obtained from the medical record
ANS: D
Subjective data is based on what patients or family members communicate to the nurse. Patient-
reported health history, signs and symptoms, and caregiver reported financial barriers would be
considered subjective data. Vital signs obtained from the medical record would be considered
objective data.
DIF: Cognitive Level: Understanding (Comprehension) TOP: Nursing Process: Planning MSC: NCLEX:
Management of Client Care
4. The nurse is generating solutions (planning) for a patient who has chronic lung disease and
hypoxia. The patient has been admitted for increased oxygen needs above a baseline of 2 L/min.
The nurse generates an expected outcomes stating, “The patient will have oxygen saturations of
>95% on room air at the time of discharge from the hospital.” What is wrong with this goal?
a. It cannot be evaluated.
b. It is not measurable.
c. It is not patient-centered.
d. It is not realistic.
ANS: D
The expected outcome is not realistic because the patient is not usually on room air and should
not be expected to attain that expected outcome by discharge from this hospitalization.
DIF: Cognitive Level: Applying (Application) TOP: Nursing Process: Planning MSC: NCLEX:
Management of Client Care
5. Which of the following would be correctly categorized as objective data?
a. A list of herbal supplements regularly used provided by the patient.
